Dong-Yu Gao
Affiliations: | 2013-2015 | Biomedical Engineering | National Tsing Hua University, Hsinchu City, Taiwan, ROC |
Google:
"Dong-Yu Gao"
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Sung YC, Jin PR, Chu LA, et al. (2019) Delivery of nitric oxide with a nanocarrier promotes tumour vessel normalization and potentiates anti-cancer therapies. Nature Nanotechnology |
Sung YC, Liu YC, Chao PH, et al. (2018) Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics. 8: 894-905 |
Chih-Chun C, Yang Y, Gao DY, et al. (2017) Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl4-induced hepatic fibrosis in Mice. Journal of Drug Targeting. 1-27 |
Chen Y, Liu YC, Sung YC, et al. (2017) Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Scientific Reports. 7: 44123 |
Lin TT, Gao DY, Liu YC, et al. (2015) Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. Journal of Controlled Release : Official Journal of the Controlled Release Society |
Liu JY, Chiang T, Liu CH, et al. (2015) Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy |
Gao DY, Lin TT, Sung YC, et al. (2015) CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 67: 194-203 |
Chen Y, Gao DY, Huang L. (2015) In vivo delivery of miRNAs for cancer therapy: challenges and strategies. Advanced Drug Delivery Reviews. 81: 128-41 |